PT3481819T - Compostos e a sua utilização para reduzir os níveis de ácido úrico - Google Patents

Compostos e a sua utilização para reduzir os níveis de ácido úrico

Info

Publication number
PT3481819T
PT3481819T PT178248563T PT17824856T PT3481819T PT 3481819 T PT3481819 T PT 3481819T PT 178248563 T PT178248563 T PT 178248563T PT 17824856 T PT17824856 T PT 17824856T PT 3481819 T PT3481819 T PT 3481819T
Authority
PT
Portugal
Prior art keywords
compounds
uric acid
acid levels
reducing uric
reducing
Prior art date
Application number
PT178248563T
Other languages
English (en)
Original Assignee
Acquist Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acquist Llc filed Critical Acquist Llc
Publication of PT3481819T publication Critical patent/PT3481819T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT178248563T 2016-07-06 2017-07-06 Compostos e a sua utilização para reduzir os níveis de ácido úrico PT3481819T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662358669P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
PT3481819T true PT3481819T (pt) 2022-08-12

Family

ID=60913101

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178248563T PT3481819T (pt) 2016-07-06 2017-07-06 Compostos e a sua utilização para reduzir os níveis de ácido úrico

Country Status (13)

Country Link
US (3) US10688095B2 (pt)
EP (1) EP3481819B1 (pt)
JP (1) JP7006960B2 (pt)
KR (1) KR102444538B1 (pt)
CN (1) CN109476642B (pt)
BR (1) BR112019000201A2 (pt)
CA (1) CA3029883A1 (pt)
DK (1) DK3481819T3 (pt)
ES (1) ES2925186T3 (pt)
MX (1) MX2018014718A (pt)
PT (1) PT3481819T (pt)
TW (1) TWI749024B (pt)
WO (1) WO2018009615A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI771303B (zh) * 2016-06-30 2022-07-21 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(一)
KR102444538B1 (ko) * 2016-07-06 2022-09-16 애퀴스트 엘엘씨 요산 수치를 감소시키기 위한 화합물 및 이의 사용
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
SG11202000532SA (en) * 2017-08-09 2020-02-27 Denali Therapeutics Inc Compounds, compositions and methods
PE20212023A1 (es) 2019-02-13 2021-10-18 Denali Therapeutics Inc Compuestos, composiciones y metodos
TW202136237A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
CN114989087A (zh) * 2021-03-01 2022-09-02 中国科学院上海有机化学研究所 一种含氟羟基喹啉类化合物的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944667A (en) 1972-09-08 1976-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Formylazapentadienenitriles
DE2832698A1 (de) 1978-07-26 1980-02-07 Bayer Ag Substituierte 5-phenylcarbamoyl- barbitursaeuren, verfahren zu ihrer herstellung und ihre verwendung als insektizide
ZA849819B (en) * 1983-12-19 1985-07-31 Uniroyal Inc 5-pyrimidinecarboxamides and thiocarboxamides and treatment of leukemia and tumors therewith
IL73840A (en) 1983-12-19 1988-11-15 Uniroyal Chem Co Inc 2-thio-5-(thio)carbamoyl barbituric acid derivatives,their preparation and pharmaceutical compositions containing them
US4879276A (en) * 1983-12-19 1989-11-07 Uniroyal Chemical Ltd./Uniroyal Chemical Ltee Method for reducing serum uric acid levels
CH657015A5 (de) 1984-06-27 1986-08-15 Ciba Geigy Ag Motten- und kaeferschutzmittel.
GB2171099B (en) 1985-02-15 1988-10-19 Ciba Geigy Ag 5-(azolyloxphenylcarbamoyl)barbituric acid derivatives as anthelmintics
US4636508A (en) 1985-04-22 1987-01-13 Uniroyal Chemical Company, Inc. 5-pyrimidinecarboxyamides and treatment of leukemia therewith
US4880811A (en) 1987-06-24 1989-11-14 Memorial Hospital For Cancer And Allied Diseases Use of C-5 mono-substituted barbiturates to treat disorders of uric acid metabolism
AU7540991A (en) * 1990-03-09 1991-10-10 Memorial Hospital For Cancer And Allied Diseases C-5 mono-substituted barbiturates in combination with therapeutic agents and uses thereof
CN1295227C (zh) 1997-06-21 2007-01-17 罗赫诊断器材股份有限公司 具有抗转移和抗肿瘤活性的巴比土酸衍生物
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
MX2010011591A (es) 2008-04-22 2010-11-09 Astrazeneca Ab Pirimidin-5-carboxamidas sustituidas 281.
US9428466B2 (en) 2013-11-13 2016-08-30 Raymond P. Warrell, Jr. Methods for reducing uric acid levels using barbiturate derivatives
EP3104861A4 (en) 2014-02-14 2017-10-04 Warrell, Raymond P., Jr. Bifunctional compounds and use for reducing uric acid levels
CN107108526A (zh) * 2015-01-22 2017-08-29 R·P·小沃勒尔 双功能化合物及用于降低尿酸水平的用途
TWI771303B (zh) * 2016-06-30 2022-07-21 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(一)
KR102444538B1 (ko) * 2016-07-06 2022-09-16 애퀴스트 엘엘씨 요산 수치를 감소시키기 위한 화합물 및 이의 사용

Also Published As

Publication number Publication date
JP2019520387A (ja) 2019-07-18
BR112019000201A2 (pt) 2019-07-09
WO2018009615A9 (en) 2018-06-28
US20190117654A1 (en) 2019-04-25
US20200268757A1 (en) 2020-08-27
EP3481819A1 (en) 2019-05-15
DK3481819T3 (da) 2022-07-25
ES2925186T3 (es) 2022-10-14
KR102444538B1 (ko) 2022-09-16
KR20190025612A (ko) 2019-03-11
MX2018014718A (es) 2019-04-11
EP3481819A4 (en) 2020-02-19
US11020397B2 (en) 2021-06-01
TW201805282A (zh) 2018-02-16
US20210236495A1 (en) 2021-08-05
US20200197393A9 (en) 2020-06-25
JP7006960B2 (ja) 2022-01-24
CN109476642B (zh) 2022-01-25
CN109476642A (zh) 2019-03-15
EP3481819B1 (en) 2022-06-01
CA3029883A1 (en) 2018-01-11
US10688095B2 (en) 2020-06-23
WO2018009615A1 (en) 2018-01-11
TWI749024B (zh) 2021-12-11

Similar Documents

Publication Publication Date Title
HK1255102A1 (zh) 雜環化合物及其應用
SI3334422T1 (sl) Uporaba kanabidiolne kisline pri zdravljenju epilepsije
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
PT3481819T (pt) Compostos e a sua utilização para reduzir os níveis de ácido úrico
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
GB201519088D0 (en) The use of bacteria formulations
GB201514760D0 (en) Compounds and method of use
HK1215797A1 (zh) 尿酸值下降劑
HK1232145A1 (zh) 雙功能化合物和用於降低尿酸水平的用途
IL255054A0 (en) Tetrahydronephthyridinyl propionic acid derivatives and their uses
SG11201610413RA (en) Lactic acid bacteria suppressing purine absorption and use thereof
EP3197885A4 (en) Heterocyclic compounds and use thereof
EP3247704A4 (en) Bifunctional compounds and use for reducing uric acid levels
IL252355A0 (en) Low dose a2a antagonist for the treatment of adhd and parkinson
GB201603546D0 (en) Treatment of urine
PT3268356T (pt) Compostos heterocíclicos e métodos para a sua utilização
PL3297622T3 (pl) Kombinacje oksykodonu i n-acyloetanoloaminy palmitoiloetanoloaminy do zmniejszenia skutków ubocznych związanych z opioidami
PL2975004T3 (pl) Obróbka kwasowych ścieków
IL258458B (en) Peroxyhemiacetal profragrant and proflavor compounds
GB201514770D0 (en) Compounds and their use
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
AU2015903010A0 (en) Heterocyclic Compounds and Methods for their Use
AU2015902922A0 (en) Heterocyclic compounds and methods for their use
AU2015902886A0 (en) Heterocyclic Compounds And Methods For Their Use